$599

Teplizumab BLA Re-submission Accepted by FDA; March 21-24 CHMP Agenda

Two cardiometabolic-related news items have been observed: Provention Bio announced FDA has accepted the resubmitted teplizumab BLA for the delayed onset of T1DM; and the CHMP agenda for this month’s meeting (March 21-24) has been released. Below, FENIX provides highlights and insights for the respective new items.

This content is for Read Less members only.
Register
Already a member? Log in here